TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Conclusion This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy. Micro-Abstract Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: August–September 2018Source: Medicina Intensiva (English Edition), Volume 42, Issue 6Author(s): F.D. Martos-Benítez, A. Gutiérrez-Noyola, M. Badal, N.A. DietrichAbstractObjectivesTo determine the risk factors for severe acute respiratory failure requiring invasive mechanical ventilation (SARF-MV) and its effect upon clinical outcomes in critically ill cancer patients.DesignA retrospective cohort study was carried out.SettingA 12-bed oncological intensive care unit (ICU) from January 2014 to December 2015.PatientsA total of 878 consecutive cancer patients were included. Patients with an...
Source: Medicina Intensiva - Category: Intensive Care Source Type: research
Publication date: August–September 2018Source: Medicina Intensiva (English Edition), Volume 42, Issue 6Author(s): A. Carmona-Bayonas, F. Gordo, C. Beato, J. Castaño Pérez, P. Jiménez-Fonseca, J. Virizuela Echaburu, J. Garnacho-MonteroAbstractCancer patients are a vulnerable group exposed to numerous and serious risks beyond cancer itself. In recent years, the prognosis of these individuals has improved substantially thanks to several advances such as immunotherapy, targeted molecular therapies, surgical techniques, or developments in support treatment. This coincides with the prolonged survival o...
Source: Medicina Intensiva - Category: Intensive Care Source Type: research
SKIN cancer symptoms are triggered when skin cells start to divide uncontrollably. There are two main types of skin cancer, called melanoma and non-melanoma skin cancer. Watch out for this major warning sign of skin cancer.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Emma Neagu, now 14, from Toronto, was diagnosed with a form of bone cancer known as osteosarcoma in 2016. The teen endured nine months of grueling chemotherapy.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
This article focused on the CML and epigenetic and clinical significance. An electronic search of peer-reviewed articles was systematically performed to obtain the relevant literature with the CINAHL, cancer, Google scholar, self-experience and PubMed databases. The keywords included leukemia, cancer, illness, epigenetic. The inclusion criteria for the reviews were that the documents were original quantitative research and published in English. Articles that were not directly relevant to the present objective were excluded. Current progress in molecular biology and bioinformatics offer novel promising experiments namely as...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Authors: Steckiewicz KP, Barcińska E, Woźniak M Abstract Nerve growth factor (NGF) is protein discovered by Rita Levi Montalcini in the 1950s. It plays a crucial role in the development of nervous system. NGF may be produced by a variety of cells even beyond nervous system. NGF modulate cell metabolism by binding to p75NTR and TrkA receptors. NGF is involved in psychological processes and may be the possible therapeutical agent for diabetes, cancer and cardiovascular diseases, which will be described in the article. PMID: 30030957 [PubMed - in process]
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Abstract Essential facts Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. The main categories are lymphoma, leukaemia, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms. In addition, there are subtypes of lymphoma and leukaemia, as well as more rare haematological cancers that have their own categories. There are also borderline conditions such as aplastic anaemia and other non-malignant bone marrow failure syndromes. The charity Bloodwise says 38,000 people in Britain are diagnosed every year with blood cancer or a related disor...
Source: Nursing Standard - Category: Nursing Authors: Tags: Nurs Stand Source Type: research
Conclusion In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in twelve patients (18%). HCS identification provides insight for improved and individualized treatment, and screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis, and advocates that with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germline testing. Teaser The clinical importance and anticipated results of geneti...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in 12 patients (18%). HCS identification provides insight for improved and individualized treatment, as well as screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis; with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germ-line testing. PMID: 27210295 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Conclusion Lenalidomide appears to yield a higher HI-E rate in non-del5q LR-MDS when used as first-line therapy after ESA treatments failure. If validated in larger cohorts, lenalidomide rather than azacitidine should be considered for first-line therapy after ESA treatment failure. Micro-Abstract In patients with lower-risk myelodysplastic syndromes (LR-MDS) in whom treatment with erythropoiesis-stimulating agents (ESAs) fail, optimal sequencing of lenalidomide and azanucleosides is unknown. In a retrospective analysis of patients who received azacitidine and lenalidomide, the erythroid hematologic improvement rate was 3...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants